Login to Your Account

Neurovance, Otsuka find common ground in ADHD

By Marie Powers
News Editor

Friday, March 3, 2017

Privately held Neurovance Inc. struck a potential $250 million acquisition deal with Otsuka Pharmaceutical Co. Ltd. on the basis of a single asset in ADHD.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription